February 26, 2024 BERN, Switzerland, and BOSTON  — Ikerian AG and RetinAI Inc. US, a developer of software solutions for image processing and artificial intelligence (AI) in ophthalmology, has launched RetinAI Discovery for Clinics, with
February 22, 2024 NEW YORK, N.Y. – A large language model (LLM) artificial intelligence (AI) system can match, or in some cases outperform, human ophthalmologists in the diagnosis and treatment of patients with glaucoma and
February 21, 2024 MASSAPEQUA PARK, N.Y. —  The Ocular Wellness and Nutrition Society (OWNS), a nonprofit organization dedicated to advancing eye health through nutrition and wellness, has announced the next phase expansion of its advisory
February 14, 2024 LONDON and NEW YORK – OKYO Pharma Limited has announced that the U.S. Food and Drug Administration (FDA) has cleared OK-101 as its first Investigational New Drug (IND) application for the treatment
February 14, 2024 BEDFORD, Mass. — Ocular Therapeutix, Inc. has announced that the first three subjects have been screened and received their first aflibercept injection in the Phase 3 SOL-1 clinical trial of AXPAXLI (axitinib intravitreal implant, also known
February 14, 2024 LONDON and NEW YORK — MeiraGTx Holdings, a vertically integrated, clinical stage gene therapy company, announced the achievement of the first milestone payment of $50 million under the asset purchase agreement the company entered
February 13, 2024 NEW YORK— Eyenovia, Inc. has announced that the company’s facility in Redwood City, Calif., successfully completed FDA inspection for approval as a commercial manufacturing facility. The Redwood City facility will primarily be
February 1, 2024 IRVINE, Calif., and COLORADO SPRINGS, Colo., —  OcuLenz, the new AR/XR headset from Ocutrx Technologies, Inc., is set for commercial release in the first half of this year. The headset has been
February 1, 2024 CHICAGO — Prevent Blindness has declared February as Age-related Macular Degeneration (AMD) and Low Vision Awareness Month. The group is offering a variety of free educational resources to the public and professionals, including fact
January 26, 2024 DES MOINES, Iowa – Kemin Industries, a global ingredient manufacturer, was highlighted in a published study on the efficacy of spearmint extract for nutritional support in neural tissues in a model of hypertensive
